Current Development Status of MEK Inhibitors

被引：191

作者：

Cheng, Ying

Tian, Hongqi ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China

来源：

MOLECULES | 2017年 / 22卷 / 10期

关键词：

MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study; ACTIVATED PROTEIN-KINASE; I DOSE-ESCALATION; PREVIOUSLY TREATED PATIENTS; REFAMETINIB BAY 86-9766; BRAF-MUTANT MELANOMA; CELL LUNG-CANCER; PHASE-I; PIMASERTIB MSC1936369B/AS703026; SELUMETINIB AZD6244; OPEN-LABEL;

D O I：

10.3390/molecules22101551

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.

引用

页数：20

共 97 条

[1] Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate) [J].

Abe, Hiroyuki ;

Kikuchi, Shinichi ;

Hayakawa, Kazuhide ;

Iida, Tetsuya ;

Nagahashi, Noboru ;

Maeda, Katsuya ;

Sakamoto, Johei ;

Matsumoto, Noriaki ;

Miura, Tomoya ;

Matsumura, Koji ;

Seki, Noriyoshi ;

Inaba, Takashi ;

Kawasaki, Hisashi ;

Yamaguchi, Takayuki ;

Kakefuda, Reina ;

Nanayama, Toyomichi ;

Kurachi, Hironori ;

Hori, Yoshikazu ;

Yoshida, Takayuki ;

Kakegawa, Junya ;

Watanabe, Yoshihiro ;

Gilmartin, Aidan G. ;

Richter, Mark C. ;

Moss, Katherine G. ;

Laquerre, Sylvie G. .

ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (04) :320-324

[2] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors [J].

Adjei, Alex A. ;

LoRusso, Patricia ;

Ribas, Antoni ;

Sosman, Jeffrey A. ;

Pavlick, Anna ;

Dy, Grace K. ;

Zhou, Xiaofei ;

Gangolli, Esha ;

Kneissl, Michelle ;

Faucette, Stephanie ;

Neuwirth, Rachel ;

Bozon, Viviana .

INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) :47-58

[3] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].

ALESSI, DR ;

CUENDA, A ;

COHEN, P ;

DUDLEY, DT ;

SALTIEL, AR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494

[4]

[Anonymous], [No title captured]

[5]

Antonio M.G., 2017, AM J CLIN DERMATOL

[6] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].

Ascierto, Paolo A. ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabrielle ;

Di Giacomo, Anna Maria ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Yan, Yibing ;

Wongchenko, Matthew ;

Chang, Ilsung ;

Hsu, Jessie J. ;

Koralek, Daniel O. ;

Rooney, Isabelle ;

Ribas, Antoni ;

Larkin, James .

LANCET ONCOLOGY, 2016, 17 (09) :1248-1260

[7] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[8] Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial [J].

Awada, A. ;

Delord, J. P. ;

Houede, N. ;

Lebbe, C. ;

Lesimple, T. ;

Schellens, J. H. M. ;

Rottey, S. ;

Kefford, R. ;

Rejeb, N. ;

Raymond, E. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 :185-186

[9] A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study [J].

Banerjee, Anuradha ;

Jakacki, Regina I. ;

Onar-Thomas, Arzu ;

Wu, Shengjie ;

Nicolaides, Theodore ;

Poussaint, Tina Young ;

Fangusaro, Jason ;

Phillips, Joanna ;

Perry, Arie ;

Turner, David ;

Prados, Michael ;

Packer, Roger J. ;

Qaddoumi, Ibrahim ;

Gururangan, Sridharan ;

Pollack, Ian F. ;

Goldman, Stewart ;

Doyle, Lawrence A. ;

Stewart, Clinton F. ;

Boyett, James M. ;

Kun, Larry E. ;

Fouladi, Maryam .

NEURO-ONCOLOGY, 2017, 19 (08) :1135-1144

[10] The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 [J].

Barrett, Stephen D. ;

Bridges, Alexander J. ;

Dudley, David T. ;

Saltiel, Alan R. ;

Fergus, James H. ;

Flamme, Cathlin M. ;

Delaney, Amy M. ;

Kaufman, Michael ;

LePage, Sophie ;

Leopold, Wilbur R. ;

Przybranowski, Sally A. ;

Sebolt-Leopold, Judith ;

Van Becelaere, Keri ;

Doherty, Annette M. ;

Kennedy, Robert M. ;

Marston, Dan ;

Howard, W. Allen, Jr. ;

Smith, Yvonne ;

Warmus, Joseph S. ;

Tecle, Haile .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (24) :6501-6504

← 1 2 3 4 5 6 7 8 9 10 →